Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

NCT02863328 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02863328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02863328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
August 10, 2016
Completion date
March 8, 2018
Enrollment
822 (actual)
Sites
106

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2